{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:06Z","timestamp":1791908406267,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To assess the incidence, clinical characteristics, and post-progression management strategy of resistance to immunotherapy\u2013chemotherapy combination in unresectable biliary tract carcinoma (uBTC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Experimental<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design<\/jats:title>\n            <jats:p>Patients with uBTC from multiple centers who received immunotherapy\u2013chemotherapy combination were retrospectively included. Baseline characteristics, treatments, pattern of progression, and posttreatment managements were recorded. The primary endpoint was post-progression survival (PPS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of 194 patients, 130 (67.0%) developed resistance, including 78 (40.2%) with acquired resistance (AR) and 52 (26.8%) with primary resistance (PR). Normal CA19-9 level and combining target therapy were more common in patients with AR. Patients with both AR and PR commonly experience deterioration in general condition and systemic progression. Patients with AR and PR showed no difference in patterns of progression or current post-progression management strategies. A total of 103 (79.2%) patients receiving post-resistance antitumor treatments showed improved prognosis than those receiving best supportive care, while patients with AR received additional survival benefit than those with PR. Changing immunotherapy regimen after resistance brings significant survival benefit in patients with AR (mPPS: 15.1 vs. 9.50 months, HR\u2009=\u20090.41), but not those with PR. Adding\/switching target therapy regimens (HR\u2009=\u20090.39) and local regional therapies (LRT) (HR\u2009=\u20090.36) after resistance brings potential benefit in patients with PR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Changing immunotherapy regimen is a promising strategy for overcoming AR to first-line immunotherapy\u2013chemotherapy combination in uBTC, while adjusting targeted therapy and adding LRT may help overcome PR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00262-025-04181-2","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:01:08Z","timestamp":1759129268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Xiangqi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"1","key":"4181_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI et al (2021) Cholangiocarcinoma [J]. Nat Rev Dis Primers 7(1):65","journal-title":"Nat Rev Dis Primers"},{"issue":"10272","key":"4181_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B et al (2021) Biliary tract cancer [J]. Lancet 397(10272):428\u2013444","journal-title":"Lancet"},{"issue":"8","key":"4181_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1(8):EVIDoa2200015","journal-title":"NEJM Evid"},{"issue":"10391","key":"4181_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865","journal-title":"Lancet"},{"issue":"1","key":"4181_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D et al (2023) Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study [J]. Signal Transduct Target Ther 8(1):106","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4181_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD (2020) Acquired Resistance to Immune Checkpoint Inhibitors [J]. Cancer Cell 37(4):443\u2013455","journal-title":"Cancer Cell"},{"key":"4181_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","author":"HM Kluger","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML et al (2020) Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000398","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4181_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma [J]. N Engl J Med 375(9):819\u2013829","journal-title":"N Engl J Med"},{"issue":"2","key":"4181_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","volume":"46","author":"S George","year":"2017","unstructured":"George S, Miao D, Demetri GD et al (2017) Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma [j]. Immunity 46(2):197\u2013204","journal-title":"Immunity"},{"issue":"6","key":"4181_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","volume":"13","author":"SN Gettinger","year":"2018","unstructured":"Gettinger SN, Wurtz A, Goldberg SB et al (2018) Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer. J Thorac Oncol 13(6):831\u2013839","journal-title":"J Thorac Oncol"},{"issue":"11","key":"4181_CR11","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, Lamberti G, Puchala SR et al (2024) Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer [J]. J Clin Oncol 42(11):1311\u20131321","journal-title":"J Clin Oncol"},{"issue":"5","key":"4181_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000505933","volume":"43","author":"HY Kuo","year":"2020","unstructured":"Kuo HY, Chiang NJ, Chuang CH et al (2020) Impact of immune checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on organ-specific efficacy and macrovascular invasion in advanced hepatocellular carcinoma [J]. Oncol Res Treat 43(5):211\u2013220","journal-title":"Oncol Res Treat"},{"issue":"5","key":"4181_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","volume":"9","author":"J Hyung","year":"2023","unstructured":"Hyung J, Kim I, Kim KP et al (2023) Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b nifty randomized clinical trial [J]. JAMA Oncol 9(5):692\u2013699","journal-title":"JAMA Oncol"},{"issue":"26","key":"4181_CR14","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1200\/JCO.23.01566","volume":"42","author":"TJ Ettrich","year":"2024","unstructured":"Ettrich TJ, Modest DP, Sinn M et al (2024) Nanoliposomal irinotecan with fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced cholangiocarcinoma: a phase II study of the AIO hepatobiliary-YMO cancer groups (NIFE-AIO-YMO HEP-0315) [J]. J Clin Oncol 42(26):3094\u20133104","journal-title":"J Clin Oncol"},{"issue":"6","key":"4181_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim RD, Chung V, Alese OB et al (2020) A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract cancer [J]. JAMA Oncol 6(6):888\u2013894","journal-title":"JAMA Oncol"},{"issue":"11","key":"4181_CR16","doi-asserted-by":"publisher","first-page":"e1565","DOI":"10.1093\/oncolo\/oyae154","volume":"29","author":"C Jing","year":"2024","unstructured":"Jing C, Bai Z, Tong K et al (2024) Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study. Oncologist 29(11):e1565\u2013e1574","journal-title":"Oncologist"},{"issue":"8","key":"4181_CR17","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ijc.34372","volume":"152","author":"S Jin","year":"2023","unstructured":"Jin S, Zhao R, Zhou C et al (2023) Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: an open-label, single-arm, phase II clinical trial. Int J Cancer 152(8):1648\u20131658","journal-title":"Int J Cancer"},{"issue":"20","key":"4181_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki (2013) ethical principles for medical research involving human subjects [J]. JAMA 310(20):2191\u20132194","journal-title":"JAMA"},{"issue":"4","key":"4181_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J et al (2020) Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 9(4):414\u2013424","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"4181_CR20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ijrobp.2022.03.019","volume":"113","author":"Y Chen","year":"2022","unstructured":"Chen Y, Wei M, Shen S et al (2022) The combination of radiation therapy and immunotherapy is effective and well-tolerated for unresectable biliary tract cancer. Int J Radiat Oncol Biol Phys 113(4):816\u2013824","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4181_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.907055","volume":"12","author":"X Ding","year":"2022","unstructured":"Ding X, Li G, Sun W et al (2022) Sintilimab combined with lenvatinib for advanced intrahepatic cholangiocarcinoma in second-line setting-a multi-center observational study. Front Oncol 12:907055","journal-title":"Front Oncol"},{"issue":"3_suppl","key":"4181_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2024.42.3_suppl.488","volume":"42","author":"J Fan","year":"2024","unstructured":"Fan J, Zhou J, Shi G et al (2024) A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a primary analysis. J Clin Oncol 42(3_suppl):488","journal-title":"J Clin Oncol"},{"issue":"5","key":"4181_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ (2019) Toripalimab: first global approval. Drugs 79(5):573\u2013578","journal-title":"Drugs"},{"key":"4181_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109292","volume":"14","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xue J, Wang Y et al (2023) Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer [J]. Front Immunol 14:1109292","journal-title":"Front Immunol"},{"issue":"3","key":"4181_CR25","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143\u2013e152","journal-title":"Lancet Oncol"},{"issue":"17","key":"4181_CR26","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1158\/1078-0432.CCR-22-0657","volume":"28","author":"AJ Schoenfeld","year":"2022","unstructured":"Schoenfeld AJ, Rizvi HA, Memon D et al (2022) Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer. Clin Cancer Res 28(17):3797\u20133803","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4181_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4637","volume":"5","author":"N Zhuo","year":"2022","unstructured":"Zhuo N, Liu C, Zhang Q et al (2022) Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer. JAMA Netw Open 5(3):e224637","journal-title":"JAMA Netw Open"},{"issue":"5","key":"4181_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000536549","volume":"13","author":"TH Liu","year":"2024","unstructured":"Liu TH, Chen SC, Rau KM et al (2024) Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression. Liver Cancer 13(5):509\u2013521","journal-title":"Liver Cancer"},{"issue":"2","key":"4181_CR29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/liv.15117","volume":"42","author":"F Tovoli","year":"2022","unstructured":"Tovoli F, GARAJOV\u00e1 I, Gelsomino F et al (2022) Pattern of progression of intrahepatic cholangiocarcinoma: implications for second-line clinical trials. Liver Int 42(2):458\u2013467","journal-title":"Liver Int"},{"key":"4181_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.03.018","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Z, Wu J et al (2025) A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. https:\/\/doi.org\/10.1016\/j.cell.2025.03.018","journal-title":"Cell"},{"issue":"2","key":"4181_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D et al (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer [J]. Cancer Cell 42(2):209\u201324.e9","journal-title":"Cancer Cell"},{"issue":"6702","key":"4181_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C et al (2024) Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384(6702):eadf1329","journal-title":"Science"},{"issue":"4","key":"4181_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N et al (2023) The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients [J]. Cancer Cell 41(4):711\u201325.e6","journal-title":"Cancer Cell"},{"issue":"10","key":"4181_CR34","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jamaoncol.2020.2169","volume":"6","author":"P Ravi","year":"2020","unstructured":"Ravi P, Mantia C, Su C et al (2020) Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma [J]. JAMA Oncol 6(10):1606\u20131610","journal-title":"JAMA Oncol"},{"issue":"7","key":"4181_CR35","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.21873\/anticanres.13543","volume":"39","author":"K Fujita","year":"2019","unstructured":"Fujita K, Uchida N, Yamamoto Y et al (2019) Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Res 39(7):3917\u20133921","journal-title":"Anticancer Res"},{"issue":"7","key":"4181_CR36","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/1759-7714.13483","volume":"11","author":"S Kitagawa","year":"2020","unstructured":"Kitagawa S, Hakozaki T, Kitadai R et al (2020) Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer 11(7):1927\u20131933","journal-title":"Thorac Cancer"},{"issue":"8","key":"4181_CR37","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK et al (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial [J]. Nat Med 27(8):1410\u20131418","journal-title":"Nat Med"},{"issue":"11","key":"4181_CR38","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/2159-8290.CD-23-0951","volume":"13","author":"KM Mulvaney","year":"2023","unstructured":"Mulvaney KM (2023) Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A\/MTAP-Deleted Cancers [J]. Cancer Discov 13(11):2310\u20132312","journal-title":"Cancer Discov"},{"issue":"6","key":"4181_CR39","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jhep.2023.08.017","volume":"79","author":"W Limousin","year":"2023","unstructured":"Limousin W, Laurent-Puig P, Ziol M et al (2023) Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab\/bevacizumab. J Hepatol 79(6):1450\u20131458","journal-title":"J Hepatol"},{"issue":"1","key":"4181_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3350\/cmh.2020.0095","volume":"27","author":"GS Yoo","year":"2021","unstructured":"Yoo GS, Ahn WG, Kim SY et al (2021) Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: a murine model study. Clin Mol Hepatol 27(1):144\u2013156","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4181_CR41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D et al (2022) Radiotherapy combined with immunotherapy: the dawn of cancer treatment [J]. Signal Transduct Target Ther 7(1):258","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4181_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101232","volume":"7","author":"M Wu","year":"2025","unstructured":"Wu M, Fulgenzi CAM, D\u2019alessio A et al (2025) Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab\/bevacizumab. JHEP Rep 7(2):101232","journal-title":"JHEP Rep"},{"issue":"2","key":"4181_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4143\/crt.2019.493","volume":"52","author":"J Kang","year":"2020","unstructured":"Kang J, Jeong JH, Hwang HS et al (2020) Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response [J]. Cancer Res Treat 52(2):594\u2013603","journal-title":"Cancer Res Treat"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04181-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04181-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04181-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:08:18Z","timestamp":1760962098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04181-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4181"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04181-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki, and it was approved by the Institutional Review Board of PUMCH (No. I-24PJ2728, I-24PJ2730, and I-25PJ0158) and PLAGH (No. KY-2025\u20131-18\u20131). All patients provided written informed consent before receiving ICI\u2013chemotherapy combination and relevant target\/LRTs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"320"}}